ID 249264996 · FY 2019–2024 · 6 years
Iveriapharma (ივერიაფარმა, iveriapharma.com) — a small Georgian pharmaceutical manufacturer producing natural-origin antiviral, antibacterial and antifungal medicines (including a Cyclamen-extract active ingredient). Very low revenue against a stable production asset base; an R&D-driven producer rather than a distributor or pharmacy.
curated 2026-06-25
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|
| Total Revenue | 172 | 226 | 178 | 228 | 22 | 395 | +18.0% |
| Total COGS | -93 | -246 | -117 | -265 | -5 | -296 | +26.1% |
| Gross Profit | 80 | -20 | 61 | -37 | 17 | 99 | +4.5% |
| Gross Margin | 46.2% | -9.0% | 34.2% | -16.3% | 76.8% | 25.1% | |
| Total Operating Expenses | -255 | -252 | -269 | -266 | -557 | -464 | +12.7% |
| EBITDA | -176 | -272 | -208 | -303 | -540 | -365 | +15.7% |
| EBITDA Margin | -102.0% | -120.4% | -117.0% | -133.3% | -2415.3% | -92.4% | |
| Total D&A | -49 | -58 | -61 | -67 | -69 | -70 | +7.6% |
| EBIT / Operating Income | -224 | -330 | -269 | -371 | -609 | -435 | +14.2% |
| Total Interest Income | 0 | 0 | 0 | 0 | 3 | 3 | +17.3% |
| Total Interest Expense | 0 | 0 | 0 | 0 | -18 | -28 | +51.3% |
| Total Other Income | 2,692 | -14 | 49 | 77 | -37 | 6 | nmf |
| Profit Before Tax | 2,468 | -344 | -220 | -293 | -662 | -453 | nmf |
| Total Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | |
| Net Profit / (Loss) | 2,517 | -286 | -159 | -226 | -577 | -358 | nmf |
| Net Margin | 1462.1% | -126.7% | -89.4% | -99.3% | -2581.0% | -90.8% |
Ownership & directors from companyinfo.ge (public corporate registry).